Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US14070B3096
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000DZMK99
CAPR
Capricor Therapeutics, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Capricor Therapeutics, Inc.
ISIN
US14070B3096
TICKER
CAPR
MIC
XNAS
REUTERS
CAPR.OQ
BLOOMBERG
CAPR US
Mi., 05.08.2026       Capricor Therapeutics
US14070B3096

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, both dates inclusive (the “Class Period”), have until September 28, 2026 to seek appointment as lead plaintiff of the Capicor class action lawsuit. Caption...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 04.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 4, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 04.08.2026       Capricor Therapeutics
US14070B3096

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 incl...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 04.08.2026       Capricor Therapeutics
US14070B3096

Law Offices of Howard G. Smith reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Capricor Therapeutics, Inc. ("Capricor" or the “Company”) (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). IF YOU...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 04.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 4, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vio...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 04.08.2026       Capricor Therapeutics
US14070B3096

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) common stock between December 17, 2025 and July 26, 2026, inclusive (“the Class Period”).If you suffered a loss on your Capricor investments, you have u...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 03.08.2026       Capricor Therapeutics
US14070B3096

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ:CAPR) and certain of the company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.If you invested in C...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 03.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 3, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 03.08.2026       Capricor Therapeutics
US14070B3096

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). Capricor is a biotechnology company.For more information, submit a form, email attorney Phillip Kim, or g...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 03.08.2026       Capricor Therapeutics
US14070B3096

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 3, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.CLASS DEFINITION: The l...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 03.08.2026       Capricor Therapeutics
US14070B3096

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). Capricor investors have until September...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 03.08.2026       Capricor Therapeutics
US14070B3096

The Law Offices of Frank R. Cruz reminds investors of the upcoming September 28, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Capricor Therapeutics, Inc. ("Capricor" or the Company") (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclu...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 03.08.2026       Capricor Therapeutics
US14070B3096

The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. (“Capricor” or “the Company”) (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CAPR d...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 01.08.2026       Capricor Therapeutics
US14070B3096

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. (“Capricor” or “the Company”) (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 01.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - July 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Capricor Therapeutics Inc. (NASDAQ: CAPR) resulting from allegations that Capricor may have issued materially misleading business information to the inv...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 01.08.2026       Capricor Therapeutics
US14070B3096

Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period").The lawsuit alleges that Capricor Therapeutics misled investors regarding the pa...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 01.08.2026       Capricor Therapeutics
US14070B3096

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NasdaqGS: CAPR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 31.07.2026       Capricor Therapeutics
US14070B3096

Capricor (NASDAQ: CAPR) shares collapsed 60% to 70% on July 27, 2026 after FDA staff briefing documents raised significant concerns regarding the evidence supporting Deramiocel's efficacy ahead of the July 29, 2026 advisory committee meeting. CAPR shareholders who saw their investment drop after the FDA briefing documents are encouraged to act prom...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 31.07.2026       Capricor Therapeutics
US14070B3096

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). Capricor investors have until September 28, 2026 to file a lead plai...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 31.07.2026       Capricor Therapeutics
US14070B3096

Boston, Massachusetts--(Newsfile Corp. - July 31, 2026) - Block & Leviton is investigating Capricor Therapeutics (NASDAQ: CAPR) for potential securities law violations. Investors who have lost money in their Capricor Therapeutics investment should contact the firm to learn more about how they might recover those losses. For more details, visit...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 31.07.2026       Capricor Therapeutics
US14070B3096

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned Nkamga v. Capricor Therapeutics, Inc., et al., on behalf of persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NA...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 31.07.2026       Capricor Therapeutics
US14070B3096

Glancy Prongay Wolke & Rotter LLP (“GPWR”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned Nkamga v. Capricor Therapeutics, Inc., et al., on behalf of persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (“Capricor” or the...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 30.07.2026       Capricor Therapeutics
US14070B3096

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Capricor Therapeutics, Inc. (NASDAQ:CAPR) for potential securities fraud after its significant stock drop.If you invested in Capricor Therapeutics securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/capric...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 30.07.2026       Capricor Therapeutics
US14070B3096

Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely disclose material information to investors. What if I purchased Capricor securities? If you purchased Capricor s...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 30.07.2026       Capricor Therapeutics
US14070B3096

SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not suppor...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 29.07.2026       Capricor Therapeutics
US14070B3096

--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings-- --Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Primary Endpoint, with Deramiocel Slowing Upper Limb Function Decline by 54 Percent versus Placebo (PUL 2.0, p=0.03) and Showing Clinically Meaningful Ca...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 29.07.2026       Capricor Therapeutics
US14070B3096

Boston, Massachusetts--(Newsfile Corp. - July 29, 2026) - Block & Leviton is investigating Capricor Therapeutics (NASDAQ: CAPR) for potential securities law violations. Investors who have lost money in their Capricor Therapeutics investment should contact the firm to learn more about how they might recover those losses. For more details, visit...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 29.07.2026       Capricor Therapeutics
US14070B3096

Instrument ID [8264] (4LN2 - US14070B3096) suspended...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 28.07.2026       Capricor Therapeutics
US14070B3096

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONE...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 28.07.2026       Capricor Therapeutics
US14070B3096

Law Offices of Howard G. Smith announces an investigation on behalf of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CAPRICOR THERAPEUTICS, INC. (CAPR), CONTACT THE LAW OFFICES OF HOWARD G. S...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 28.07.2026       Capricor Therapeutics
US14070B3096

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) resulting from allegations that Capricor may have issued materially misleading business information to the investing public. So What: If you purchased Capricor s...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 28.07.2026       Capricor Therapeutics
US14070B3096

The Law Offices of Frank R. Cruz announces an investigation of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CAPRICOR THERAPEUTICS, INC. (CAPR), CLICK HERE TO INQUIRE ABOUT POTENTIALL...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 27.07.2026       Capricor Therapeutics
US14070B3096

SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today provided an update ahead of the Company's upcoming FDA Advisory Committee meeting, at which an independent advisory committee will discuss Capricor's Biol...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 26.06.2026       Capricor Therapeutics
US14070B3096

–Advisory Committee meeting scheduled for July 29, 2026––Company's Biologics License Application on track with PDUFA target action date of August 22, 2026–...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 26.06.2026       Capricor Therapeutics
US14070B3096

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Du...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 12.05.2026       Capricor Therapeutics
US14070B3096

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the first quarter ended March 31, 2026, and provided a corporate update....
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 04.05.2026       Capricor Therapeutics
US14070B3096

– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET –...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Capricor Therapeutics
US14070B3096

SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced additional analyses and new functional outcomes data from the Phase 3 HOPE-3 clinical trial of Deramiocel in Duchenne muscular...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 10.03.2026       Capricor Therapeutics
US14070B3096

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has lifted the previously issued Complete Response Letter and resumed revie...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 10.03.2026       Capricor Therapeutics
US14070B3096

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has lifted the previously issued Complete Response Letter and resumed revie...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Capricor Therapeutics
US14070B3096

– Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET –...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 24.02.2026       Capricor Therapeutics
US14070B3096

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that results from its Phase 3 HOPE-3 clinical study of Deramiocel in Duchenne muscular dystrophy (DMD) have been selected for a...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 20.01.2026       Capricor Therapeutics
US14070B3096

SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today provided a regulatory update regarding its Biologics License Application (BLA) for Deramiocel, the Company’s investigational first-in-cla...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 16.12.2025       Capricor Therapeutics
US14070B3096

– Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET –...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 05.12.2025       Capricor Therapeutics
US14070B3096

SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $25.00 per share. Capricor also granted th...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 03.12.2025       Capricor Therapeutics
US14070B3096

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive topline results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel, the Company’s investigational cell therap...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 03.11.2025       Capricor Therapeutics
US14070B3096

–Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development– ...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 31.10.2025       Capricor Therapeutics
US14070B3096

Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 25.09.2025       Capricor Therapeutics
US14070B3096

SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced a regulatory update for its Biologics License Application (BLA) for Deramiocel, the Company’s investigational cell therapy for the treatment of...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 15.09.2025       Capricor Therapeutics
US14070B3096

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) and reminds investors of the September 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company...
Zur Nachricht
Capricor Therapeutics
Charts & Research Termsheets Terminal
Permalink